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Abstract
Background: Isolation of novel retroviral restriction factors will open new avenues for anti-HIV/
AIDS treatment. Although HIV-1 replication is restricted by APOBEC3G/APOBEC3F, TRIM5α,
and CD317, none defend HIV-1 infection under natural conditions. Previously, we demonstrated a
host factor from the human T cell line CEM.NKR that potently restricted wild-type HIV-1
replication. Interestingly, this restriction resembled the APOBEC3G/APOBEC3F pattern in that
viral replication was inhibited from the second round of replication cycle at a post-entry step.
Results: Here, we further characterized this factor and found it distinguishable from the known
anti-HIV APOBEC3 proteins. Although CEM.NKR cells expressed both APOBEC3G and
APOBEC3F, their levels were at least 10 or 4-fold lower than those in H9 cells, and importantly,
Vif effectively neutralized their activity. Among eight subclones isolated from CEM.NKR cells, one
was relatively permissive, four were semi-permissive, and three were completely non-permissive
for HIV-1 replication. When the levels of APOBEC3 expression were determined, all these clones
retained similar low levels of APOBEC3DE, APOBEC3F, APOBEC3G and APOBEC3H expression,
and no APOBEC3B expression was detected. Since the vif from SIVmac can effectively neutralize
APOBEC3B and APOBEC3H, recombinant HIV-1 expressing this SIV gene were created. However,
these viruses still failed to replicate in CEM.NKR cells. We also confirmed that HIV-1 restriction
in CEM.NKR was not due to a loss of calnexin expression.
Conclusion: Taken together, these results not only demonstrate that all these aforementioned
anti-HIV APOBEC3 proteins do not contribute to this HIV-1 restriction, but also shed light on a
novel and potent HIV-1 inhibitor in CEM.NKR cells.
Background
CEM is a human T lymphosarcoma cell line isolated from
an infant female patient with acute leukemia [1]. This
human T cell line has been useful in HIV research because
of its infectability and has significantly contributed to our
understanding of innate intracellular immunity to retrovi-
ruses. Human T cell lines have been classified as either
permissive or non-permissive cells based on their ability
to support vif-deficient HIV-1 replication. CEM and H9
are non-permissive cell lines, whereas Sup-T1 and Jurkat
are permissive lines [2,3]. Derivative cell lines have been
isolated from CEM by various methods, including CEM-
SS [4], CEM-T4, A3.01 [5], and CEM.NKR [6]. Interest-
ingly, both CEM-SS and CEM-T4 are permissive for vif-
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deficient HIV-1 replication whereas A3.01 is semi-permis-
sive [7], suggesting that the original CEM cells are quite
heterogeneous. Importantly, genetic analysis of the differ-
ence between CEM and CEM-SS has led to the discovery
of APOBEC3G (A3G) as one of the cellular targets of Vif
[8].
A3G belongs to a small group of proteins in the cytidine
deaminase family known as the APOBEC3 (A3) subfamily
[9]. This group of proteins includes A3A, A3B, A3C, A3DE,
A3F, A3G, and A3H. All have antiretroviral activities
against different targets including exogenous retroviruses
and endogenous retroelements [10]. A3B, A3DE, A3F, and
A3G contain two Zinc-binding motifs, while A3A, A3C,
and A3H contain only one. A3B, A3DE, A3F, and A3G
inhibit HIV-1 replication to different degrees, whereas
A3A and A3C do not [8,11-16]. Recently, it was shown
that A3H also inhibits HIV-1 replication if its expression
is optimized in cell culture [17-20]. Among these pro-
teins, the anti-HIV activity of A3G and A3F is the most
prominent. Nevertheless, HIV-1 is able to elude this
defense mechanism and cause human disease for two rea-
sons. First, A3B and A3H are poorly expressed in vivo
[13,17,21,22]. Second, HIV-1 produces Vif, which binds
to and mediates the destruction of A3DE, A3F, and A3G in
26S proteasomes via recruitment of the Cullin5 ubiquitin
E3 ligase [23,24]. Vif may also inhibit A3 activity inde-
pendent of proteasomal degradation [25-27]. In addition
to Vif activity, HIV-1 replication can also be inhibited by
two other types of restriction factors: TRIM5α which
blocks viral uncoating [28] and cell surface protein
CD317 which blocks viral release [29]. However, human
TRIM5a does not inhibit HIV-1, and the antiviral activity
of CD317 is neutralized by another viral protein Vpu.
CEM.NKR is a naturally isolated cell clone from CEM that
is resistant to natural killer (NK) cell-mediated lysis [6].
Previously, we tried to infect CEM.NKR cells and found
that they were highly resistant to productive infection by
wild-type HIV-1 [30]. Further analyses indicated that
CEM.NKR expressed a viral inhibitor, which did not target
incoming viruses but blocked HIV-1 at the second round
of replication at a post-entry step. Since this inhibitor
showed a similar inhibition profile as A3G/A3F except
that it inhibited the wild-type virus, we wondered whether
this resistance was simply due to an over-expression or
expression of a genetic variant of known A3 cytidine
deaminases which could not be inhibited by Vif. Here, we
present several different lines of evidence to demonstrate
that this inhibitor activity is indeed novel and distinguish-
able from any of A3 proteins.
Results and discussion
Over-expression of A3G/A3F is not responsible for wild-
type HIV-1 restriction in human T cells
To further understand the mechanism of HIV-1 restriction
in CEM.NKR, we first determined whether CEM.NKR cells
secreted a soluble factor that inhibited HIV-1 replication.
Since H9 cells can be productively infected by wild-type
HIV-1, we set up a co-culture system between H9 and
CEM.NKR to address this issue. After a brief incubation
with wild-type virus, infected H9 or CEM.NKR cells were
co-cultured by either mixing together (CEM.NKR+H9) or
separated by a permeable membrane (H9/CEM.NKR) in a
24-well plate and viral production assayed as p24Gag syn-
thesized was monitored for 11 days. H9 cells alone were
productively infected with peak viral production at ~500
ng/ml p24Gag, whereas CEM.NKR cells alone were poorly
infected with maximal viral production at ~5 ng/ml
p24Gag (Fig. 1A). These results were consistent with our
previous observations [30]. In addition, H9/CEM.NKR
and CEM.NKR+H9 co-cultures were both productively
infected, and viral production from the H9/CEM.NKR co-
culture was slightly higher than that of H9 alone or the
CEM.NKR+H9 co-culture (Fig. 1A). This result indicated
that CEM.NKR cells did not secrete a soluble HIV-1 inhib-
itor.
Second, we compared A3G/A3F protein levels in H9 and
CEM.NKR cells to determine whether A3G/A3F were
overly expressed in CEM.NKR cells. Cell lysates were pre-
pared from a total of 1 × 107 H9 or CEM.NKR cells. Two-
fold serial dilutions were analyzed by Western blotting
using A3G or A3F-specific antibody. Actin served as a
loading control. Surprisingly, the levels of both A3G and
A3F in CEM.NKR cells were around 10 or 4-fold lower
than those in H9 cells, respectively (Fig. 1B). This result
indicated that restriction of HIV-1 replication in
CEM.NKR was not due to over-expression of A3G and
A3F. We next determined whether A3G or A3F genes con-
tained mutations that would reduce their sensitivity to Vif
and contribute to the HIV-1 non-permissiveness in
CEM.NKR. A3G and A3F cDNAs were amplified from
CEM.NKR by RT-PCR and cloned for sequencing. Interest-
ingly, it was found that the A3G gene contained a R14Q
and A3F contained a Q275E mutation. To test how these
mutations affected A3G and A3F, these genes were cloned
into pcDNA3.1 assayed for their effect on HIV-1 in a sin-
gle round replication cycle. Wild-type and vif-deficient
HIV-1 luciferase reporter viruses were produced from
293T cells in the presence of the wild-type or mutant A3G
or A3F expression vectors. Equal amounts of viruses were
collected to infect GHOST cells and viral infectivity was
determined by measuring cellular luciferase activities.
Compared to the infectivity of the control HIV-1 pro-
duced in the absence of any A3G/A3F proteins, all A3G
and A3F proteins (wild-type and mutants) reduced theRetrovirology 2009, 6:31 http://www.retrovirology.com/content/6/1/31
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HIV-1ΔVif virus infectivity significantly more than HIV-1
virus infectivity (Fig. 1C). For example, A3G, A3G R14Q,
A3F, or A3F Q275E reduced HIV-1 infectivity by 12, 8, 60,
or 16-fold and HIV-1ΔVif infectivity by 260, 60, 270, or
80-fold respectively. Although these results might indicate
that A3G R14Q and A3F Q275E had slightly lower anti-
HIV-1 activity, these proteins were still sensitive to Vif.
Third, we wanted to directly demonstrate that Vif could
neutralize A3G/A3F in CEM.NKR cells. Our strategy was
to create HIV-1 and HIV-1ΔVif virus-infected CEM.NKR
cells and compare levels of G-to-A mutations in HIV-1
genomes. If the HIV-1 contained lower levels of mutations
than the HIV-1ΔVif, it should further confirm A3G/A3F
sensitivity to Vif. Since CEM.NKR cells were very difficult
Characterization of inhibitory activity of CEM.NKR Figure 1
Characterization of inhibitory activity of CEM.NKR. A) CEM.NKR cells do not secrete a soluble HIV inhibitory factor. 
Either 2 × 105 H9 or CEM.NKR cells were infected with 150 ng p24Gag of HIV-1 (NL4-3) for 3 hours at 37°C individually. After 
extensive washing, they were either cultured in separated wells, co-cultured by mixing them in the same well (CEM.NKR+H9) 
at 1:1 ratio, or co-cultured in the same well at 1:1 ratio separated by a insert with a 1.0 μm transparent PET membrane (H9/
CEM.NKR) in 24-well plates (BD Biosciences). Viral production was determined by p24Gag ELISA over an 11-day period. B) 
CEM.NKR cells express lower levels of A3G and A3F than H9. Cytosolic fractions were prepared from equal numbers of 
CEM.NKR and H9 cells and the cytosol from H9 was subjected to a two-fold serial dilution. The levels of A3G and A3F expres-
sion were analyzed by Western blotting. The levels of actin contained lysate from 5 × 106 cells (undiluted lanes) served as an 
internal control. C) A3G R14Q and A3F Q275E mutants retain anti-HIV-1 activity. The cDNAs of A3G R14Q and A3F Q275E 
were amplified from CEM.NKR by RT-PCR and cloned into pcDNA3.1/V5-His-TOPO vector (Invitrogen). Wild-type or vif-
defective HIV-1 (NL4-3) were produced from 293T cells in the presence of these wild-type or mutant A3G or A3F proteins 
and viral infectivity was determined in GHOST cells. Ctrl, control vector (pcDNA3.1). D) Vif effectively inactivates A3G/A3F in 
CEM.NKR cells. H9 and CEM.NKR cells were infected with HIV-1 or vif-deficient HIV-1 (NL4-3) expressing a neomycin-resist-
ant gene in the nef gene locus and infected cells were selected by G418 treatment. HIV genes from nucleotides 5693 to 5912 
corresponding to pNL4-3 sequence were amplified from these infected cells by PCR. After cloning into TA-cloning vector, 
multiple clones were collected for nucleotide sequencing. The type of mutation is summarized in tabular form, where the orig-
inal HIV-1 sequence is given at left, and the new sequence is given across the top. N at the lower right of each box indicates the 
total numbers of bases sequenced.
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to infect, they were infected with HIV-1 or HIV-1ΔVif
viruses expressing a neomycin-resistance gene (pNL-Neo,
pNL-NeoΔVif) and infected cells were amplified by G418
treatment. As controls, H9 cells were infected and treated
similarly. After that, cellular DNAs were extracted and HIV
genes were amplified by PCR and cloned into a T-A clon-
ing vector for sequencing. It was found that all viral
genomes contained much higher rates of G-to-A of muta-
tions than any other mutations (Fig. 1D). Further analyses
found that these excessive G-to-A mutations occurred in
both GG and GA dinucleotides (data not shown), which
are preferred mutation sites for A3G and A3F. In addition,
the G-to-A hypermutation rate was much higher in H9
than CEM.NKR cells, which was consistent with the
higher A3G/A3F expression levels in H9 cells. Moreover,
when Vif was present, this G-to-A hypermutation rate was
reduced to half in both H9 and CEM.NKR cells (Fig. 1D).
These results clearly indicated that Vif could neutralize
A3G/A3F activity in CEM.NKR cells as efficiently as in H9
cells, and they also pointed out that a complete elimina-
tion of their activities by Vif might not be possible in these
human T cells. Thus, we concluded that HIV-1 resistance
in CEM.NKR was not due to the inability of Vif to neutral-
ize A3G/A3F.
Analysis of HIV-1 resistance in CEM.NKR subpopulations
Although we knew that CEM.NKR cells were resistant to
productive HIV infection, we also found that they could
become productively infected if they were exposed to pro-
longed viral infection (Fig. 2A). After 10 days, viral pro-
duction jumped from lower than 100 to 1000 ng/ml
p24Gag, which was similar to levels of viral production in
CEM-T4 cells. Although CEM.NKR was reported as a
cloned cell line [6], we suspected that its cell population
might be heterogenous. A limiting dilution assay was used
to assess CEM.NKR homogenicity. Eight clones were iso-
HIV-1 resistance in CEM.NKR subpopulations Figure 2
HIV-1 resistance in CEM.NKR subpopulations. A) HIV-1 (NL4-3) replication in CEM.NKR and CEM-T4 cells over a 16-
day period. B) HIV-1 replication in cell clones from CEM.NKR. CEM.NKR cells were subjected to limiting dilution and eight cell 
clones (#1 to #8) were isolated. Together with CEM-T4 and the parental CEM.NKR, these clones were infected with HIV-1 
(NL4-3) and viral production was measured for 32 days. C) CD4 and CXCR4 surface expression in cell clones from 
CEM.NKR. The parental or each individual cell clone was stained with fluorescence-conjugated antibodies (CD4-FITC, 
CXCR4-PE) and analyzed by flow cytometry.
g
A
B
C
CEM.NKR clone #1
clone #8 clone #7 clone #6
clone #5 clone #4 clone #3
clone #2
01 0
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
01 0
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
01 0
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
01 0
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
01 0
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
01 0
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
01 0
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
01 0
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
01 0
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
CD4-FITC
#6
Days postinfection
0.1
1
10
100
1000
10000
0 2 4 6 8 1 01 21 41 61 82 02 22 42 62 83 03 2
CEM-T4
CEM.NKR
#1
#2
#3 #4
#5
#7
#8
Days postinfection
0.1
1
10
100
1000
10000
0 2 4 6 8 1 01 21 41 6
CEM-T4
CEM.NKRRetrovirology 2009, 6:31 http://www.retrovirology.com/content/6/1/31
Page 5 of 12
(page number not for citation purposes)
lated which were subsequently inoculated with HIV-1 and
cultured for 32 days. It was found that all clones as well as
the parental CEM.NKR showed delayed viral replication
kinetics compared to the highly permissive CEM-T4 cell
lines [7]. However, using 100 ng/ml of p24Gag as a crite-
rion for productive infection, we could divide these clones
into three groups based on how long it took to become
productively infected (Fig. 2B). For example, clone #5 as
well as the parental CEM.NKR cells were designated as
permissive cells since they only took 10 days to become
productively infected; clones #4, #7, #8, and #1 cells were
designated as semi-permissive cells since they took 16 to
28 days to become productively infected; and clones #2,
#3, and #6 cells were designated as non-permissive cells
since they were not productively infected even after 32
days. It was confirmed that all these clones expressed com-
parable levels of CD4 and CXCR4 as the parental cell line,
although clone #2 and #8 expressed higher levels of
CXCR4 (Fig. 2C). Thus, CEM.NKR cells contained a subset
of cells that were relatively permissive for HIV-1 replica-
tion.
Lack of correlation of A3 expression with HIV-1 replication 
in CEM.NKR cell clones
Since we obtained several CEM.NKR clones that could be
productively infected by HIV-1, we next compared wild-
type and vif-deficient HIV-1 replication to understand
how A3 cytidine deaminases function in these cells. As we
reported previously, wild-type and vif-deficient HIV-1 rep-
licated equally well in CEM-T4 cells [7] (Fig. 3A). Consist-
Activity and expression of A3 cytidine deaminases in cell clones from CEM.NKR Figure 3
Activity and expression of A3 cytidine deaminases in cell clones from CEM.NKR. A) Wild-type and vif-defective 
HIV-1 replication in CEM.NKR cell subpopulations. A total of 2 × 105 of CEM-T4, CEM.NKR, and the eight clones were 
infected with 150 ng p24Gag of wild-type or vif-defective HIV-1 (NL4-3) and viral production was measured for 16 days. B) A3G 
and A3F protein expression in CEM.NKR and its cell clones determined by Western blotting. C) A3DE and A3H mRNA 
expression in CEM.NKR and its cell clones as determined by real-time PCR. Results are presented as relative values, where 
expression levels in H9 cells are set as 100%.
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ently, wild-type HIV-1 started productive replication in
parental CEM.NKR and clone #5 from 8 to 10 days postin-
fection, and in clones #4 and #7 from 16 days postinfec-
tion. Notably, the vif-deficient HIV-1 failed to replicate in
all these cell lines. This result further confirmed that Vif
could effectively neutralize A3G/A3F proteins in
CEM.NKR as well as its derived cell clone #4, #5, and #7.
To further address whether the HIV-1 resistance in the
other non-permissive cell clones was due to an over-
expression of any A3 cytidine deaminases, we measured
protein expression levels of A3G and A3F by Western blot-
ting and mRNA expression levels of A3B, A3DE, and A3H
by real-time PCR. It was found that all these cell clones
except clone #6 expressed similar levels of A3G and A3F as
the parental CEM.NKR (Fig. 3B). Our real-time PCR anal-
ysis failed to detect A3B in any of these cell clones as well
as in H9, CEM-SS, and the parental CEM.NKR, confirming
that A3B is poorly expressed in vivo. The mRNA levels of
A3DE were quite similar in CEM-SS, parental CEM.NKR,
and these cell clones, except that levels of A3DE mRNA in
H9 and clone #7 were approximately 5-fold higher (Fig.
3C). In addition, the mRNA levels of A3H in CEM-SS,
CEM.NKR, and these cell clones were 100 to 1000-fold
lower than those in H9 except that clone #7 expressed
slightly higher A3H mRNA (Fig. 3C). Since clones #6 and
#7 exhibited a non-permissive or semi-permissive pheno-
type for HIV-1 infection (Fig. 2B), respectively, we there-
fore further confirmed that levels of A3 expression did not
correlate with HIV-1 resistance in CEM.NKR and its sub-
clones.
Calnexin does not rescue HIV-1 replication in CEM.NKR 
cells
It was reported that CEM.NKR cells lose a cellular protein
called calnexin (CANX), a type I transmembrane protein
that plays a role in the retention of misfolded glycopro-
teins in the endoplasmic reticulum (ER) [31]. CANX is
found to interact with the uncleaved HIV-1 gp160 glyco-
protein [32], and it was speculated that CANX might func-
tion as a gp160 chaperone that could play a role during
viral entry [33]. To understand whether HIV restriction in
CEM.NKR was due to the loss of CANX, CEM.NKR cells
were transduced with an exogenous CANX gene contain-
ing a 3'-HA tag expressed from a retroviral vector pMSCV-
neo and stably transduced cells were obtained by G418
selection. Using the same procedure, CEM.NKR cells were
also transduced with a green fluorescence protein (GFP)
gene, and CEM-T4 and CEM-SS cells were transduced with
the same CANX gene, were used as controls. CANX and
GFP proteins were all expressed in these cells as deter-
mined by Western blotting (Fig. 4A). When these cell lines
were infected with HIV-1, it was found that CEM.NKR
HIV-resistance in CEM.NKR is not due to the loss of calnexin expression Figure 4
HIV-resistance in CEM.NKR is not due to the loss of calnexin expression. A) Transduction of calnexin gene into 
CEM.NKR cells. Calnexin (CANX) or a control (GFP) gene with a 3'-HA tag was cloned into the pMSCVneo retroviral vector. 
Recombinant retroviruses were produced by transfection of the Phoenix-AMPHO cell line and were used to infect CEM.NKR, 
CEM-T4, and CEM-SS cells. Four stable cell lines were created by G418 selection and the expressions of transduced genes 
were determined by Western blotting using an anti-HA antibody. B) HIV-1 (NL4-3) replication in these four cell lines.
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cells expressing GFP and CANX were almost equally resist-
ant to viral infection, whereas CEM-SS and CEM-T4 cells
expressing CANX were productively infected (Fig. 4B).
This result demonstrated that expression of CANX could
not rescue HIV replication in CEM.NKR and excluded that
the blockade of viral entry was an explanation for HIV-1
restriction in our previous observation [30].
CEM.NKR cells express a HIV-1 inhibitor
Previously, we demonstrated that CEM.NKR cells
expressed a HIV-1 inhibitor using a cell fusion assay [30].
In this assay, 293T cells expressing HIV-1 gp160 were co-
cultured with CEM.NKR cells producing env-defective
HIV-1. Only heterokaryons formed by gp160 and CD4/
CXCR4 mediated cell fusion could release infectious par-
ticles, which could be detected by infection of the HIV
indicator cell line TZM-BI. The levels of infectious parti-
cles from heterokaryons should positively correlate with
HIV-1 resistance of the tested cell line. Notably, the levels
of infectious particles from heterokaryons should also
positively correlate with the fusion efficiency between
293T and the target T cells. We therefore assessed the
fusion efficiency of 293T with CEM.NKR as well as its sub-
clones.
293T cells were cotransfected with GFP and gp160 expres-
sion vectors, and co-cultured with CEM-SS, CEM.NKR,
clone #2, or clone #5 cells producing env-defective HIV-1,
respectively. As controls, 293T cells were only transfected
with a GFP expression vector and used in these co-cul-
tures. The number of CD4 and GFP double positive cells
were then measured by flow cytometry. The fusion effi-
ciency was calculated by the levels of double positive cells
in the co-cultures expressing gp160 after deduction from
those controls. Accordingly, CEM-SS, CEM.NKR, clone
#5, and clone #2 had 0.15%, 0.16%, 0.27%, and 0.27%
fusion efficiency with 293T cells (Fig. 5A). Thus,
CEM.NKR, clone #2, and clone #5 all had higher fusion
efficiency with 293T than CEM-SS under this condition.
We next determined the levels of infectious particles pro-
duced from these co-cultures. A2.01 cells were used as a
negative control because this cell line did not express CD4
and could not fuse with 293T cells expressing gp160 [7].
Indeed, co-cultures of 293T with A2.01, CEM.NKR, clone
#2, and clone #5 all produced very low levels of infectious
particles, whereas the co-culture of 293T with CEM-SS
produced 10 to 20-fold more infectious particles (Fig. 5B).
These results indicated that poor production of infectious
particles from co-cultures of 293T with CEM.NKR and its
subclones was not due to the poor fusion efficiency, and
instead, it was due to the presence of an HIV-1 inhibitor.
To further confirm these observations, we tried to directly
fuse these CEM.NKR clones with CEM-SS cells to see
whether viral production could be suppressed. It is known
that T-cell tropic HIV-1 can induce cell fusion and cause
syncytium-formation during infection. CEM-SS cell line is
not only highly permissive for HIV-1 infection, but also
sensitive to HIV-1-induced syncytium-formation [4].
Thus, fusion between CEM-SS and CEM.NKR cells could
occur naturally if they were co-cultured during HIV-1
infection. In addition, we tired to further increase this
fusion efficiency by treating cells with polyethylene glycol
(PEG).
Although clone #5 was the most permissive for HIV-1
infection among the CEM.NKR clones, we found that this
cell line was still much less permissive than CEM-SS (Fig.
5C). Thus, this cell line might still express the same HIV-
1 inhibitor, albeit at a decreased level. We therefore used
both clone #5 and #2 for this determination. HIV-1-
infected CEM-SS, CEM.NKR, clone #5, or clone #2 cells
were co-cultured with or without a brief PEG treatment
and viral production was determined over a 10-day
period. Even without PEG treatment, levels of virus pro-
duction were all reduced from CEM-SS+CEM.NKR, CEM-
SS+clone #5, and CEM-SS+clone #2 co-cultures, and
importantly, the reduction from CEM-SS+clone #2 was
much more significant (Fig. 5D). Since we already dem-
onstrated that CEM.NKR cells did not secrete a soluble
HIV-1 inhibitor (Fig. 1A), such reduction could be
explained by the appearance of cell fusion of CEM-SS with
CEM.NKR, clone #5, and clone #2 cells, resulting in an
inhibition of HIV-1 replication. When treated with PEG,
viral production was further reduced, which could be due
to an increase in cell fusion efficiency (Fig. 5D). These
results not only further supported our previous conclu-
sion that CEM.NKR cells expressed a HIV-1 inhibitor, but
also indicated that clone #5 could express relatively lower
levels of this inhibitor than clone #2.
The replication of HIV-1 expressing vif from SIVmac is still 
restricted in CEM.NKR cells
It is known that vif from HIV-1 does not neutralize human
A3B and A3H [11,17]. However, vif from SIVmac neutral-
izes not only human A3DE, A3F, and A3G, but also
human A3B and A3H [11,12,17,34-36]. These observa-
tions suggest that vif from SIVmac is a powerful tool to
knock down all these known anti-HIV human APOBEC3
proteins. Although we already knew that CEM.NKR cells
had low levels of A3B and A3H expression (Fig. 3C), we
wanted to further exclude that they were not responsible
for HIV-1 restriction in CEM.NKR cells.
The vif in pNL4-3 was replaced with a vif from SIVmac,
and a recombinant HIV proviral construct pNL-macVif as
well as a control pNL-hVif expressing vif from HIV-1 was
created. We first tested their sensitivity to different human
APOBEC3 proteins by a single round HIV replicationRetrovirology 2009, 6:31 http://www.retrovirology.com/content/6/1/31
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assay. Although A3B, A3G, and A3H all restricted HIV-1
replication, only A3G was effectively neutralized by vif
from HIV-1 (Fig. 6A, compare pNL-ΔVif with pNL-hVif).
In contrast, vif from SIVmac not only more effectively neu-
tralized A3G than vif from HIV-1, but also effectively neu-
tralized both A3B and A3H (Fig. 6A). These results are
consistent with previous observations.
Next, we used viruses produced from pNL-macVif to infect
several different human T cell lines. In a 16-day period,
these viruses replicated robustly in both CEM-SS cells and
CEM-SS cells expressing an exogenous A3G gene, indicat-
ing that they successfully overcame A3G restriction; they
replicated well in H9 cells, indicating that they could also
overcome A3F and A3DE restriction (Fig. 6B). Notably,
Infectivity of HIV particles from cells fused with CEM.NKR cell clones Figure 5
Infectivity of HIV particles from cells fused with CEM.NKR cell clones. A) Fusion efficiency between CEM.NKR and 
293T cells. 293T cells were transfected with a GFP expression vector in the presence or absence of gp160 expression vector 
and then co-cultured with CEM-SS, CEM.NKR, clone #2, or clone #5, respectively. After 48 hours, cells were stained with 
CD4-PE and the amounts of CD4 and GFP double positive cells were measured by flow cytometry. B) Production of infectious 
particles from heterokaryons between 293T and CEM.NKR or its subclones. The gp160-expressing 293T cells were co-cul-
tured with indicated T cells producing env-defective HIV-1. After 48 hours, production of infectious particles from these co-
cultures was determined by infection of TZM-BI cells. C) HIV-1 (NL4-3) replication in CEM-SS, CEM.NKR, clone #2, and clone 
#5 cells. D) HIV-1 (NL4-3) replication in CEM-SS and CEM.NKR co-cultures. A total of 5 × 105 HIV-infected CEM-SS, 
CEM.NKR, clone #2, or clone #5 cells were co-cultured at 1:1 ratio with or without a 5 min PEG treatment. Viral production 
from these cultures was then determined for 10 days.
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their replications in CEM.NKR cell line as well as its clones
#5 and #2 were quite similar to the wild-type HIV-1 as
seen in Fig. 2B. The relatively permissive clone #5 also
supported pNL-macVif viruses replication whereas the
non-permissive clone #2 did not. The parental CEM.NKR
cell line showed a phenotype between these two clones.
These results demonstrated that HIV-1 replication was still
restricted in CEM.NKR cells even in the presence of vif
from SIVmac, which disproved any possible role of A3B
and A3H in this HIV-1 restriction.
Conclusion
In this report, we have not only confirmed the HIV-1
inhibitor in CEM.NKR cells, but also found that it was
quite different from any known APOBEC3 proteins.
Although CEM.NKR cells expressed A3G and A3F, their
activities were effectively neutralized by HIV-1 Vif as evi-
denced by the decreased G-to-A hypermutations in the
wild-type viral genome (Fig. 1D). They, therefore, should
not be able to restrict the wild-type HIV-1 replication in
CEM.NKR cells. In addition, we found that both A3B and
A3H were poorly expressed in CEM.NKR cells (Fig. 3C and
data not shown), and importantly, HIV-1 expressing vif
from SIVmac that effectively inactivated theses two
human genes still failed to productively replicate in these
cells (Fig. 6B). These results excluded any possible contri-
bution of these APOBEC3 cytidine deaminases to this
restriction. Thus, CEM.NKR cells express a novel host fac-
tor that potently inhibit HIV-1 replication.
So far, all biologically functional retrovirus restriction fac-
tors identified in humans, including A3G/A3F [8,15,16],
TRIM5α [28], and CD317 [29], have been counteracted
by HIV-1. The A3G/A3F proteins are targeted for proteas-
omal degradation by Vif [15,16,24,37-39]; the CD317
proteins that can tether viral particles on the cell surface
are inactivated by Vpu [29]; unlike old world monkey
TRIM5α proteins, human TRIM5α proteins do not have
anti-HIV-1 activity. These facts suggest that these host fac-
tors have imposed very strong evolutionary pressures dur-
ing the cross-species transmission of HIV-1 to humans,
and the virus needs to develop counteractive mechanisms
in order to spread into humans. Why HIV-1 failed to
develop a strategy to counteract this novel factor is an
intriguing and critical question. One possibility is that it
may not be broadly expressed in human tissues, particu-
larly in the primary sites of HIV-1 replication. Among dif-
ferent CEM-derived cell lines, only CEM.NKR cells express
this factor. In addition, previous proteomics investigation
has found that CEM.NKR cells lose one cellular gene cal-
nexin [31], indicating a difference in gene expression pro-
file between CEM.NKR and its parental cell line.
Restriction of HIV-1 expressing vif fromSIVmac in CEM.NKR cells Figure 6
Restriction of HIV-1 expressing vif fromSIVmac in CEM.NKR cells. A) SIVmac vif effectively neutralized human 
APOBEC3 proteins in single cycle HIV-1 replication assay. Proviral constructs pNL-ΔVif, pNL-hVif, or pNL-macVif were co-
transfected with pcDNA3.1 (Ctrl), pcDNA-A3G, pcDNA-A3B or VR-A3H into 293T cells at 1:1 ratio. After normalized by 
p24Gag, equal amounts of viruses were used to infect TZM-BI cells, and viral infectivity was determined by measuring cellular 
luciferase activity 24 hours postinfection. Results were shown as relative values, where the infectivity of viruses produced in 
the presence of pcDNA3.1 was set as 100. B) Replication of HIV-1 expressing vif from SIVmac in different human T cell lines. A 
total of 2 × 105 cells from indicated cell lines were infected with 150 ng p24Gag of HIV-1 from pNL-macVif, and viral replications 
were determined for 16 days.
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Consistently, our biological analyses demonstrate that
CEM.NKR cells express an extra host factor. It is very for-
tunate that this factor exhibits very strong anti-HIV-1
activity. It will be very interesting to know whether the
expression of this factor is broadly inducible in various tis-
sues, particularly in CD4+ T cells and monocytes/macro-
phages. Such induction could be directly used for HIV-1
suppression. Thus, further characterization of this novel
factor and study of its anti-HIV mechanism would lead to
the discovery of a powerful antiretroviral treatment.
Methods
Plasmids, cell lines, and viruses
Constructions of HIV-1 proviral vectors pNL-Neo, pNL-
NeoΔVif, pNL Gag, and pNLΔEnv were described before
[30]. Human APOBEC3 expression vectors pcDNA3.1-
A3B and A3G and VR-A3H were described before [12,17].
The calnexin gene with a 3' HA tag was inserted into the
MuLV expression vector pMSCVneo by EcoRI/XhoI diges-
tion to create pMSCVneo-CANX. pMSCVneo-GFP was
described before [7]. To create pNL-hVif and pNL-macVif,
pNL4-3 NotI/XbaI was first generated. This plasmid con-
tains a NotI site at the end of pol and XbaI site in front of
vpr and the three ATG codons in vif overlapping with pol
were silenced. After that, the vif from SIVmac and HIV-1
were then inserted by NotI/XbaI digestion to create pNL-
macVif and pNL-hVif.
The HIV indicator cell line TZM-BI and human T cell lines
H9, CEM-SS, CEM-T4, CEM.NKR, and A2.01 were from
NIH AIDS Research and Reference Reagent Program. The
CEM-SS (A3G) cell line was described before [7].
CEM.NKR clones #1, #2, #3, #4, #5, #6, #7, and #8 were
isolated by limiting dilution of CEM.NKR cells in a 96-
well culture plate. The HIV-infected H9 and CEM.NKR cell
lines were generated by infecting these cells with viruses
from pNL-Neo or pNL-Neo Vif followed by G418 selec-
tion. CEM.NKR (GFP), CEM.NKR (CANX), CEM-T4
(CANX), and CEM-SS (CANX) cell lines were generated by
infecting these cells with viruses from pMSCVneo-CANX
or pMSCVneo-GFP followed by G418 selection. T cells
were cultured in RPMI 1640 with 10% fetal bovine serum
(HyClone). 293T and TZM-BI were cultured in DMEM
with 10% bovine calf serum (HyClone).
HIV-1 or MuLV viruses were produced from 293T or Phoe-
nix-AMPHO cells by the standard calcium phosphate
transfection.
Antibodies
The polyclonal anti-human A3G antibody was from W.
Greene through the AIDS Research and Reference Reagent
Program. The mouse anti-human A3F polyclonal anti-
body was from Abnova, Taiwan. Other antibodies used
included a polyclonal rabbit anti-actin antibody (C-11)
(Santa Cruz Biotechnology), PE-conjugated mouse anti-
human CXCR4 and FITC-conjugated mouse anti-human
CD4 (BD Biosciences), HRP-conjugated anti-HA (Roche
Applied Science), and HRP-conjugated anti-rabbit,
human, or mouse IgG secondary antibodies (Pierce).
Detection of the HRP-conjugated antibody was per-
formed using Supersignal Wetpico Chemiluminescence
Substrate kit (PIERCE).
HIV-1 infection of human T cell lines
A total of 2 × 105 cells were inoculated with 100 ng p24Gag
of HIV-1 viruses at 37°C for three hours. After removal of
the inocula followed by three times of extensive washing,
cells were cultured in 24-well plates. Culture supernatants
were then collected daily for measurement of p24Gag by
ELISA.
Sequencing of viral genes
Total cellular DNAs were extracted from HIV-infected H9
and CEM.NKR cells by the DNeasy tissue kit (Qiagen). A
420-bp fragment was PCR-amplified by a previously
described primer pair [16] and cloned into the pCR4-
TOPO vector (Invitrogen). Multiple clones were selected
and sequenced by the flanking T3 and T7 primers.
Real-time PCR measurement of viral reverse transcripts
A3DE, A3H, or GAPDH (Glyceraldehyde 3-phosphate
dehydrogenase)-specific PCR primer pairs as well as an
A3H-specific fluorescence-labeled probe were described
previously [12,17]. The sequence of A3DE-specific fluo-
rescence-labeled probe is 5'-/56-FAM/CGCTCAAATCTC-
CTTTGGGACACAGG/36-TAMSp/-3'. Total cellular RNAs
were extracted by TRIzol (Invitrogen) from different cell
lines. 1 μg of total RNA was subjected to reverse transcrip-
tion using Superscriptase II reverse transcriptase and
oligo(dT)12–18 as a primer (Invitrogen). A3DE and A3H
mRNAs were first determined by TaqMan® Master Mix
gene expression kit (Applied Biosystems) and then nor-
malized to the levels of GAPDH mRNA, which were deter-
mined by the SYBR Green® PCR Master Mix kit (Applied
Biosystems).
Heterokaryon formation
A previously described protocol was used [30]. Briefly,
293T cells were seeded in six-well plates at 8 × 105/well in
2 ml medium. Twelve hours later, cells were transfected
with 6 μg of HIV Env expression vector pNLΔGag and
washed with PBS four hours' later. Simultaneously, 8 ×
105 T cells were infected with 500 ng of VSV-pseudotyped
Env-defective HIV-1 from pNL Env-transfected 293T cells
at 37°C for three hours. After removal of the inocula and
extensive washing, infected T cells were added to the Env-
expressing 293T cell culture. After 48 hours, supernatants
from these co-cultures were collected to infect TZM-BIRetrovirology 2009, 6:31 http://www.retrovirology.com/content/6/1/31
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cells. Viral infectivity was finally determined by measuring
cellular luciferase activities after another 48 hours.
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